Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16INK4a immunostaining in China

被引:14
作者
Song, Fangbin [1 ,2 ,3 ]
Yan, Peisha [1 ,2 ,3 ]
Huang, Xia [1 ,2 ,3 ]
Wang, Chun [1 ,2 ,3 ]
Qu, Xinfeng [4 ]
Du, Hui [1 ,2 ,3 ]
Wu, Ruifang [1 ,2 ,3 ]
机构
[1] Peking Univ, Shenzhen Hosp, Dept Obstet & Gynecol, 1120 Lianhua Rd, Shenzhen 518036, Guangdong, Peoples R China
[2] Shenzhen PKU HKUST Med Ctr, Inst Obstet & Gynecol, Shenzhen 518036, Guangdong, Peoples R China
[3] Shenzhen Key Lab Technol Early Diag Major Gynecol, Shenzhen 518036, Guangdong, Peoples R China
[4] Peking Univ, Shenzhen Hosp, Sanming Project Med Shenzhen, Shenzhen 518036, Guangdong, Peoples R China
关键词
Human papillomavirus; Cervical cancer screening; Cervical intraepithelial neoplasia; HPV genotyping; p16; immunocytochemistry; BASE-LINE; FOLLOW-UP; WOMEN; RISK; POPULATION; PERFORMANCE; MANAGEMENT; PROGRAM;
D O I
10.1186/s12879-021-06109-4
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background Self-sampling for human papillomavirus (HPV) testing is a feasible option to improve the cervical screening coverage. However, an ideal triage method for HPV-positive self-samples does not yet exist. The aim of this study was to explore the utility of HPV genotyping and p16(INK4a) immunostaining (p16) in triaging HPV-positive self-samples, focusing on HPV-positive, cytology-negative (HPCN) women. Methods A total of 73,699 women were screened in a cervical screening project in China via SeqHPV assay on self-samples. HPV-positive women were called-back and collected cervical sample for p16 immunostaining and liquid-based cytology, those who met any result of HPV16/18+ or visual inspection with acetic acid (VIA) + or p16+ were referred for colposcopy, and HPCN women with adequate data on p16 and pathology were analyzed. A triage strategy was considered acceptable if the negative predictive value (NPV) for cervical intraepithelial neoplasia 3 or worse (CIN3+) was 98% or more, combined with an improvement of sensitivity and specificity for CIN2+/CIN3+ in reference to the comparator, being HPV16/18 + . Results A total of 2731 HPCN women aged 30-64 years were enrolled, 136 (5.0%) CIN2+ and 53 (1.9%) CIN3+ were detected. Five triage strategies met the criteria: p16+; HPV16/33+; 'HPV16+ or HPV33/58/31/35+& p16+'; 'HPV16/33+ or HPV58/31/35+& p16+'; HPV16/18/31/33/45/52/58 + & p16+. These strategies required less or similar colposcopy referrals, and less colposcopies to detected one case of CIN2+/CIN3+, achieving favorable false positive (negative) rates to the comparator. Among them, p16 staining detected 83.1% (79.2%) of underlying CIN2 + (CIN3+) in HPCN women. Moreover, three triage strategies were favorable in sensitivity and/or specificity to the 'HPV16/33+' strategy: p16+; 'HPV16+ or HPV33/58/31/35 + & p16+'; HPV16/18/31/33/45/52/58 + &p16 + . Conclusions Genotyping for HPV16/33 could be utilized to optimize the management of HPCN women. Moreover, p16 immunostaining, either alone or combined with extended genotypes, is more effective than HPV genotypes alone in the triage of HPCN women.
引用
收藏
页数:12
相关论文
共 36 条
  • [1] Role of HPV Genotype, Multiple Infections, and Viral Load on the Risk of High-Grade Cervical Neoplasia
    Adcock, Rachael
    Cuzick, Jack
    Hunt, William C.
    McDonald, Ruth M.
    Wheeler, Cosette M.
    Joste, Nancy E.
    Kinney, Walter
    Robertson, Michael
    Waxman, Alan
    Jenison, Steven
    Gage, Julia C.
    Castle, Philip E.
    Benard, Vicki
    Saslow, Debbie
    Kim, Jane J.
    Stoler, Mark H.
    Pressley, Giovanna Rossi
    English, Kevin
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2019, 28 (11) : 1816 - 1824
  • [2] The development and evaluation of a community based model for cervical cancer screening based on self-sampling
    Belinson, Jerome L.
    Wang, Guixiang
    Qu, Xinfeng
    Du, Hui
    Shen, Jingjing
    Xu, Jiajia
    Zhong, LiQun
    Yi, Ji
    Yi, Xin
    Wu, Ruifang
    [J]. GYNECOLOGIC ONCOLOGY, 2014, 132 (03) : 636 - 642
  • [3] A Standard Protocol for the Colposcopy Exam
    Belinson, Jerome Leslie
    Pretorius, Robert G.
    [J]. JOURNAL OF LOWER GENITAL TRACT DISEASE, 2016, 20 (04) : e61 - e62
  • [4] Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial
    Carozzi, Francesca
    Gillio-Tos, Anna
    Confortini, Massimo
    Del Mistro, Annarosa
    Sani, Cristina
    De Marco, Laura
    Girlando, Salvatore
    Rosso, Stefano
    Naldoni, Carlo
    Dalla Palma, Paolo
    Zorzi, Manuel
    Giorgi-Rossi, Paolo
    Segnan, Nereo
    Cuzick, Jack
    Ronco, Guglielmo
    [J]. LANCET ONCOLOGY, 2013, 14 (02) : 168 - 176
  • [5] Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study
    Castle, Philip E.
    Stoler, Mark H.
    Wright, Thomas C., Jr.
    Sharma, Abha
    Wright, Teresa L.
    Behrens, Catherine M.
    [J]. LANCET ONCOLOGY, 2011, 12 (09) : 880 - 890
  • [6] Attribution of human papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in southern China
    Chan, Paul K. S.
    Cheung, Tak-Hong
    Li, Wai-Hon
    Yu, Mei Y.
    Chan, May Y. M.
    Yim, So-Fan
    Ho, Wendy C. S.
    Yeung, Apple C. M.
    Ho, King-Man
    Ng, H. K.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (03) : 692 - 705
  • [7] Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
    de Sanjose, Silvia
    Quint, Wim G. V.
    Alemany, Laia
    Geraets, Daan T.
    Ellen Klaustermeier, Jo
    Lloveras, Belen
    Tous, Sara
    Felix, Ana
    Eduardo Bravo, Luis
    Shin, Hai-Rim
    Vallejos, Carlos S.
    Alonso de Ruiz, Patricia
    Lima, Marcus Aurelho
    Guimera, Nuria
    Clavero, Omar
    Alejo, Maria
    Llombart-Bosch, Antonio
    Cheng-Yang, Chou
    Alejandro Tatti, Silvio
    Kasamatsu, Elena
    Iljazovic, Ermina
    Odida, Michael
    Prado, Rodrigo
    Seoud, Muhieddine
    Grce, Magdalena
    Usubutun, Alp
    Jain, Asha
    Hernandez Suarez, Gustavo Adolfo
    Estuardo Lombardi, Luis
    Banjo, Aekunbiola
    Menendez, Clara
    Javier Domingo, Efren
    Velasco, Julio
    Nessa, Ashrafun
    Chichareon, Saibua C. Bunnag
    Qiao, You Lin
    Lerma, Enrique
    Garland, Suzanne M.
    Sasagawa, Toshiyuki
    Ferrera, Annabelle
    Hammouda, Doudja
    Mariani, Luciano
    Pelayo, Adela
    Steiner, Ivo
    Oliva, Esther
    Meijer, Chris J. L. M.
    Al-Jassar, Waleed Fahad
    Cruz, Eugenia
    Wright, Thomas C.
    Puras, Ana
    [J]. LANCET ONCOLOGY, 2010, 11 (11) : 1048 - 1056
  • [8] Levels of anxiety and distress following receipt of positive screening tests in Australia's HPV-based cervical screening programme: a cross-sectional survey
    Dodd, Rachael Helen
    Mac, Olivia
    Brotherton, Julia M. L.
    Cvejic, Erin
    McCaffery, Kirsten J.
    [J]. SEXUALLY TRANSMITTED INFECTIONS, 2020, 96 (03) : 166 - 172
  • [9] Evaluation of Cobas HPV and SeqHPV Assays in the Chinese Multicenter Screening Trial
    Du, Hui
    Duan, Xianzhi
    Liu, Yan
    Shi, Bin
    Zhang, Wei
    Wang, Chun
    Qu, Xinfen
    Li, Jingran
    Zhao, Chao
    Liu, Juan
    Jiang, Jing
    Jin, Hua
    Li, Hanyi
    Xiao, Aimin
    Bao, Juncui
    Duan, Lvfang
    Huang, Xia
    Luo, Hongxue
    Bian, Shuhuang
    Zhang, Lijie
    Wei, Lihui
    Belinson, Jerome L.
    Wu, Ruifang
    [J]. JOURNAL OF LOWER GENITAL TRACT DISEASE, 2021, 25 (01) : 22 - 26
  • [10] Factors associated with low adherence to cervical cancer follow-up retest among HPV plus / cytology negative women: a study in programmatic context in a low-income population in Argentina
    Gago, Juan
    Paolino, Melisa
    Arrossi, Silvina
    [J]. BMC CANCER, 2019, 19 (1)